Brickell Current Valuation

BBI
 Stock
  

USD 3.36  0.09  2.75%   

Brickell Biotech fundamentals help investors to digest information that contributes to Brickell Biotech's financial success or failures. It also enables traders to predict the movement of Brickell Stock. The fundamental analysis module provides a way to measure Brickell Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Brickell Biotech stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Brickell Current Valuation Analysis

Brickell Biotech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
 2019 2020 2021 2022 (projected)
Revenues USD7.92 M1.82 M404 K414.63 K
Revenues7.92 M1.82 M404 K414.63 K
Enterprise Value 
 = 
Market Cap + Debt 
-  
Cash 
More About Current Valuation | All Equity Analysis

Current Brickell Biotech Current Valuation

    
  (9.36 M)  
Most of Brickell Biotech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brickell Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Brickell Current Valuation Driver Correlations

Understanding the fundamental principles of building solid financial models for Brickell Biotech is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Current Valuation. Since Brickell Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Brickell Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Brickell Biotech's interrelated accounts and indicators.

Brickell Current Valuation Historical Pattern

Today, most investors in Brickell Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Brickell Biotech's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Brickell Biotech current valuation as a starting point in their analysis.
   Brickell Biotech Current Valuation   
Share
       Timeline  
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Compare to competition
In accordance with the recently published financial statements, Brickell Biotech has a Current Valuation of (9.36 Million). This is 100.07% lower than that of the sector and 100.2% lower than that of the Current Valuation industry. The current valuation for all United States stocks is 100.06% higher than that of the company.

Brickell Biotech Current Valuation Drivers

We derive many important indicators used in calculating different scores of Brickell Biotech from analyzing Brickell Biotech's financial statements. These drivers represent accounts that assess Brickell Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Brickell Biotech's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(122.58 K)(175.13 K)(541.8 K)(1.59 M)(1.83 M)(1.88 M)
Revenue Per Employee198.51 K186.74 K54.07 K527.8 K475.02 K512.52 K
Average Assets58.08 M45.63 M34.66 M25.13 M30.46 M39.21 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(12.17 M)(8.1 M)(21.75 M)(20.9 M)(39.38 M)(40.42 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(12.17 M)(8.1 M)(21.75 M)(20.9 M)(39.38 M)(40.42 M)
Earnings before Tax(12.96 M)(9.24 M)(23.88 M)(20.91 M)(39.47 M)(40.51 M)
Average Equity45.92 M23.07 M27.82 M17.91 M24.09 M32.33 M
Enterprise Value12.67 M13.45 M4.59 M22.04 M4.97 M5.1 M
Free Cash Flow(8.68 M)3.96 M(35.99 M)(20.06 M)(36.18 M)(37.14 M)
Invested Capital37.84 M(15.21 M)488 K(2.4 M)(1.98 M)(2.03 M)
Invested Capital Average32.37 M28.85 M20.09 M(1.32 M)(2.55 M)(2.62 M)
Market Capitalization23.07 M25.74 M11.72 M41.77 M26.33 M27.03 M
Tangible Asset Value79.79 M8.31 M18.14 M33.63 M29.72 M36.69 M
Working Capital59.4 M(11.82 M)7.47 M27.18 M24.79 M28.97 M

Brickell Fundamentals

About Brickell Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Brickell Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brickell Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brickell Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company was founded in 2009 and is headquartered in Boulder, Colorado. Brickell Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Brickell Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Money Flow Index Now

   

Money Flow Index

Determine momentum by analyzing Money Flow Index and other technical indicators
All  Next Launch Module

Pair Trading with Brickell Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brickell Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brickell Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving together with Brickell Biotech

0.78ABVCAbvc Biopharma Earnings Call  TomorrowPairCorr
0.88AGTCApplied Genetic Tech Fiscal Year End 22nd of September 2022 PairCorr
0.67ALBOAlbireo Pharma Earnings Call  TomorrowPairCorr

Moving against Brickell Biotech

0.75ABCAmerisourcebergen Corp Fiscal Year End 3rd of November 2022 PairCorr
0.67AAPLApple Inc Fiscal Year End 27th of October 2022 PairCorr
0.58HPQHP Inc Fiscal Year End 22nd of November 2022 PairCorr
0.57NVDANvidia Corp Tech BoostPairCorr
The ability to find closely correlated positions to Brickell Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brickell Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brickell Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brickell Biotech to buy it.
The correlation of Brickell Biotech is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brickell Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brickell Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brickell Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Brickell Biotech Piotroski F Score and Brickell Biotech Altman Z Score analysis. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
8.9 M
Quarterly Revenue Growth YOY
27.58
Return On Assets
-0.85
Return On Equity
-1.76
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.